WMSA
FOLD

Weiss Multi-Strategy Advisers’s Amicus Therapeutics FOLD Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$80K – 640
2019
Q3 		$80K Buy
+10,000
New +$109K ﹤0.01% 558
2015
Q3 		– Sell
-10,000
Closed -$142K – 430
2015
Q2 		$142K Buy
+10,000
New +$120K 0.01% 421

Other funds holding FOLD

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Weiss Multi-Strategy Advisers's FOLD Position: Q3 2017 in Review

Weiss Multi-Strategy Advisers sold out of Amicus Therapeutics (FOLD) in Q3 2017, closing a stake of 10,000 shares — an estimated $101K sold.

Weiss Multi-Strategy Advisers first reported a position in FOLD in Q3 2016 and held it in 4 quarters. The position peaked at $101K in Q2 2017. 186 funds tracked by Wall St. Rank hold FOLD as of Q3 2017.

  • Weiss Multi-Strategy Advisers reported no remaining Amicus Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 10,000 Amicus Therapeutics shares in Q3 2017, an estimated $101K.
  • Weiss Multi-Strategy Advisers first reported a position in Amicus Therapeutics in Q3 2016 and held it in 4 quarters.
  • Weiss Multi-Strategy Advisers's Amicus Therapeutics position peaked at $101K in Q2 2017.
  • 186 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2017.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2017, filed 14 Nov 2017.